SciELO - Scientific Electronic Library Online

vol.109 número8In response to the letter by Cabadas and Álvarez-Escudero about the editorial: "Will societies of anesthesiologists partake in the take-off of non-anesthesiologist administration of propofol?Endoscopic full-thickness resection for a gastric angioleiomyoma índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Revista Española de Enfermedades Digestivas

versión impresa ISSN 1130-0108

Rev. esp. enferm. dig. vol.109 no.8 Madrid ago. 2017 



Propofol sedation implementation: utility of the failure mode and effect analysis. Patient focused quality and safety

Implementación de la sedación con propofol: utilidad del análisis modal de fallos y efectos. Calidad y seguridad centrada en el paciente



Key words: Propofol sedation. Quality and safety. Failure mode and effect analysis.

Palabras clave: Sedación con propofol. Calidad y seguridad. Análisis modal de fallos y efectos.


Dear Editor,

Sedation is a key component of digestive endoscopy. While ensuring procedural safety and quality represents a primary goal, a detailed assessment of patient-focused risks and improvements is lacking on most occasions. The failure mode and effect analysis (FMEA) is a useful tool in this context as a means of raising barriers and defense mechanisms to prevent adverse events from happening.

We report the results obtained with FMEA in our unit with regard to propofol sedation implementation. We identified sedation and immediate recovery (Table 1) as the most sensitive stages. The whole process was monitored, and the established protocol monitored the process from completion of the examination and leaving the examination room to subsequent consciousness recovery (Aldrete ≥ 9) and vital sign normalization.



Forty-seven complications (3.6%) were recorded: 30 desaturation (63.8%), six hypotension (12.8%), five bradycardia (10.6%), two laryngospasm (4.3%), two adverse reaction, one tachycardia and one aspiration case in a total of 1,326 patients with a mean age of 57.81 ± 15.36 (14-92) years and low anesthetic risk (94.6% ASAI-II). They were managed with conventional support measures and did not require hospital admissions, being identified during the sedation and monitored recovery phases.



Sedation safety during digestive endoscopy has always been a concern. Protocols and various consensus guidelines are available from major scientific societies (1,2). Before a protocol is applied, its usefulness and feasibility should be assessed. In this regard, the FMEA is helpful. This tool allows the identification, evaluation and design strategies to improve potential process-related failures by analyzing their effects, causes, severity and frequency. In addition, there is a possibility of timely detection (3).


Adrián Huergo-Fernández1, Pedro Amor-Martín1 and Fernando Fernández-Cadenas2
1Department of Digestive Diseases. Hospital Álvarez-Buylla. Mieres del Camino, Asturias. Spain.
2Department of Digestive Diseases. Hospital Universitario Central de Asturias. Oviedo, Asturias. Spain



1. Dumonceau JM, Riphaus A, Schreiber F, et al. Non-anesthesiologist administration of propofol for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates Guideline - Updated June 2015. Endoscopy 2015;47:1175-89. DOI: 10.1055/s-0034-1393414.         [ Links ]

2. Igea F, Casellas JA, González-Huix F, et al. Sedación en endoscopia digestiva. Guía de práctica clínica de la Sociedad Española de Endoscopia Digestiva. Rev Esp Enferm Dig 2014;106:195-211.         [ Links ]

3. DeRosier J, Stalhandske E, Bagian JP, et al. Using health care failure mode and effect analysis: The VA National Center for Patient Safety's prospective risk analysis system. Jt Comm J Qual Improv 2002;28:248-67. DOI: 10.1016/S1070-3241(02)28025-6.         [ Links ]